Biotechnology FDA Approves Novartis’ Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors – Novartis (NYSE:NVS) Read more
Biotechnology Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors – Candel Therapeutics (NASDAQ:CADL) Read more
Biotechnology Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments – Oncotelic Therapeutics (OTC:OTLC) Read more
Biotechnology ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI) Read more